Mr. Matt Blazei reports
ZENTEK ANNOUNCES GRANT OF STOCK OPTIONS
Zentek Ltd. has granted 1.3 million options to directors, officers and employees of the company exercisable at a price of $4.25 per common share for a period of three to five years from the date of grant. The options will vest one-third on the date of grant, one-third after six months of the date of grant and one-third after 12 months of the date of grant.
About Zentek Ltd.
Zentek is a nanotechnology company developing and commercializing next-generation health care solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZENGuard, a patent-pending coating shown to have 99-per-cent anti-microbial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.
We seek Safe Harbor.
© 2022 Canjex Publishing Ltd. All rights reserved.